H.C. Wainwright has initiated coverage on PolyPid (PYPD, Financial), assigning a Buy rating and setting a price target of $11. PolyPid is noted for its pioneering PLEX technology, which serves as a versatile drug delivery platform. This technology is adaptable to a wide array of therapeutic areas, including the delivery of small molecules, proteins, peptides, and nucleic acids.
The analyst expressed that the current market valuation of PolyPid primarily reflects its lead product, D-PLEX100. However, they believe that investors are underestimating its potential, as seen in their assessment of market expectations, which are lower than what H.C. Wainwright considers justified.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for PolyPid Ltd (PYPD, Financial) is $11.33 with a high estimate of $13.00 and a low estimate of $10.00. The average target implies an upside of 309.15% from the current price of $2.77. More detailed estimate data can be found on the PolyPid Ltd (PYPD) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, PolyPid Ltd's (PYPD, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
PYPD Key Business Developments
Release Date: May 14, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- PolyPid Ltd (PYPD, Financial) successfully concluded enrollment of the Shield 2 phase 3 trial, which is a significant milestone for the company.
- The company anticipates submitting a new drug application (NDA) for Dplex 100 in early 2026, leveraging fast track and breakthrough therapy designations.
- PolyPid Ltd (PYPD) has secured $15 million in financing, extending its cash runway into the third quarter of 2025.
- There is growing interest from potential US partners for Dplex 100, indicating strong commercial potential.
- The total addressable market for Dplex 100 in the US is substantial, with over 12 million surgeries annually, providing a significant commercial opportunity.
Negative Points
- PolyPid Ltd (PYPD) reported a net loss of $8.3 million for the first quarter of 2025, an increase from the $6.4 million loss in the same period of 2024.
- Research and development expenses increased to $6.1 million, up from $5.1 million in the previous year, driven by the Shield 2 trial.
- The company has not finalized its pricing strategy for Dplex 100, which could impact future revenue projections.
- There are uncertainties regarding the FDA inspection readiness and capacity to meet demand post-launch.
- The company's cash and cash equivalents stand at $8 million, which may not be sufficient if additional funding is not secured.
